PRIMECAP MANAGEMENT CO 13D and 13G filings for BioMarin Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-12 4:01 pm Purchase | 2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 18,414,374 9.780% | 833,515 (+4.74%) | Filing |
| 2023-02-09 4:01 pm Sale | 2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 17,580,859 9.460% | -223,921 (-1.26%) | Filing |
| 2022-02-10 12:21 pm Sale | 2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 17,804,780 9.700% | -400,554 (-2.20%) | Filing |
| 2021-03-08 11:02 am Purchase | 2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 18,205,334 10.030% | 57,373 (+0.32%) | Filing |
| 2021-01-07 09:56 am Sale | 2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 18,147,961 9.997% | -38,750 (-0.21%) | Filing |
| 2020-09-10 12:00 pm Purchase | 2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO | 18,186,711 10.030% | 1,857,391 (+11.37%) | Filing |